Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $2.0 million.

  • Cartesian Therapeutics' Long-Term Investments changed 0.0% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.0 million for FY2024, which is 0.0% changed from last year.
  • Per Cartesian Therapeutics' latest filing, its Long-Term Investments stood at $2.0 million for Q3 2025, which was down 0.0% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Long-Term Investments ranged from a high of $2.0 million in Q3 2021 and a low of $2.0 million during Q3 2021
  • Its 5-year average for Long-Term Investments is $2.0 million, with a median of $2.0 million in 2021.
  • Its Long-Term Investments has fluctuated over the past 5 years, first surged by 4503.26% in 2021, then changed by 0.0% in 2022.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Long-Term Investments stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.0 million for Q2 2025, and $2.0 million during Q1 2025.